Call for Papers & Waiver Program 2025
JBBS invites pioneering biotechnology and biomedical science research that accelerates patient impact, transforms laboratory practice, and sparks interdisciplinary collaboration.
Advance the Future of Biotechnology & Biomedical Science
The Journal of Biotechnology and Biomedical Science (JBBS) is now accepting submissions for the 2025 publication cycle, including flagship issues, thematic collections, and special issues led by guest editors. We champion translational breakthroughs—from molecular diagnostics and regenerative therapeutics to AI-enabled bioinformatics and public health innovations. Authors benefit from rigorous peer review, transparent editorial communication, and immediate global visibility via open access.
Waiver Program 2025: To ensure equitable participation, JBBS offers up to 25% discounts on Article Processing Charges (APCs) for qualifying manuscripts. Emerging researchers, LMIC collaborators, and mission-aligned consortia are encouraged to apply during submission.
We invite manuscripts that push the boundaries of biotechnology and biomedical science. The 2025 Call for Papers prioritises the thematic clusters below; interdisciplinary submissions that bridge multiple clusters are highly encouraged.
Precision Genomics & Cellular Engineering
- CRISPR-derived therapeutics, base/prime editing, RNA-guided epigenetic modulation
- Single-cell multi-omics, spatial transcriptomics, and synthetic biology design
- Cellular immunotherapies, gene therapy delivery platforms, and regulatory frameworks
Biomedical Devices & Smart Biomaterials
- Bioelectronics, lab-on-chip diagnostics, wearables, and implantable monitoring
- Nanomaterials, bioactive scaffolds, and regenerative medicine interfaces
- Point-of-care innovations for resource-limited settings
Translational Pharmacology & Therapeutics
- Drug repurposing, pharmacogenomics, and personalised dosing algorithms
- Advanced drug delivery systems (exosomes, nanocarriers, stimuli-responsive platforms)
- Real-world evidence and adaptive trial design in biotech pipelines
AI, Data Sciences & Systems Biology
- Machine learning for diagnostics, biomarker discovery, and risk stratification
- Multi-omics integration, digital twins, and systems pharmacology
- Data governance, reproducibility, and FAIR principles in biomedical datasets
Public Health Biotechnology & Preparedness
- Infectious disease surveillance, vaccine platforms, and biodefense technologies
- Point-of-care molecular diagnostics for emerging pathogens
- Biomanufacturing scalability, supply chain resilience, and regulatory harmonisation
Clinical Innovation & Digital Therapeutics
- Hybrid clinical trial models, telemedicine-enabled biotech interventions
- Digital therapeutics validated by biomedical markers
- Precision nutrition, microbiome, and metabolomics-driven health strategies
Waivers ensure that financial considerations do not limit publication opportunities. JBBS evaluates waiver requests holistically, considering author affiliation, funding access, and potential societal impact.
| Waiver Tier | Eligibility Highlights | Discount | Required Documentation |
|---|---|---|---|
| Emerging Investigator | First or corresponding authors within five years of terminal degree; limited external funding | 15% | Curriculum vitae + statement of need (max 250 words) |
| Collaborative Innovation | Interdisciplinary or multi-institution projects addressing global health or sustainability challenges | 20% | Project summary + co-author affiliations |
| Global Impact Priority | Lead or co-corresponding authors based in low- and middle-income countries (World Bank classification) | 25% | Institution letter or official affiliation proof |
Waiver decisions are communicated within seven business days of request submission. Waivers apply to APC invoices issued post-acceptance.
JBBS offers flexible submission pathways to accommodate author preferences. Use the timeline below to target upcoming publication windows. Manuscripts are reviewed continuously; deadlines ensure inclusion in specific issues or thematic collections.
| Submission Window | Priority Themes | Waiver Deadline | Target Publication Issue |
|---|---|---|---|
| 1 January – 31 March 2025 | Genomics, AI-driven diagnostics, regenerative medicine | 15 March 2025 | Volume 12 Issue 2 (June 2025) |
| 1 April – 30 June 2025 | Biotech devices, nanotherapeutics, microbiome | 15 June 2025 | Volume 12 Issue 3 (September 2025) |
| 1 July – 30 September 2025 | Public health biotechnology, vaccine platforms, digital therapeutics | 15 September 2025 | Volume 12 Issue 4 (December 2025) |
| 1 October – 31 December 2025 | Open topic submissions & 2026 special issue proposals | 15 December 2025 | Volume 13 Issue 1 (March 2026) |
Follow the Instructions for Author. Gather ethics approvals, data availability statements, and waiver materials (if applicable).
Primary: ManuscriptZone portal. Alternatives include the quick submission form or email to [email protected].
Within five business days, the editorial team confirms scope fit, checks files, and assigns reviewers.
Average turnaround: 28 days. Track progress via ManuscriptZone. Revision invitations include detailed reviewer feedback and deadlines.
Approved waivers applied to the APC invoice. Formatting and proofing are completed within two business days of payment confirmation.
JBBS collaborates with leading scientists to curate special issues that illuminate emerging trends. Propose a special issue if you are coordinating a consortium, organising a conference, or leading a thematic network.
Special Issue Proposal Requirements
- Proposed title, scope, and rationale (500 words)
- Lead Guest Editor bios (up to three editors) and affiliations
- Targeted author groups or partner organisations
- Proposed timeline and anticipated article types
Support JBBS Provides
- Dedicated editorial coordinator and promotional strategy
- Call for Papers landing page and email outreach to relevant authors
- Discounted APC packages for invited submissions (subject to approval)
- Cross-promotional opportunities with JBBS membership partners
How to Propose
- Email [email protected] with subject “JBBS Special Issue Proposal 2025”
- Include supporting materials and desired launch date
- Expect an editorial response within 10 business days
Beyond waiver incentives, JBBS offers a high-touch publishing experience crafted for credibility-driven authors.
Instructions for Author
Templates, checklists, and formatting standards for JBBS submissions.
Access GuidelinesArticle Processing Charges
Understand APC coverage, waiver policies, and payment timelines.
Review APC DetailsLanguage Editing Service
Optional professional editing to refine language and formatting.
Explore ServicesHow do I know if my manuscript qualifies for the waiver program?
Include a short justification in your cover letter outlining eligibility criteria (career stage, affiliation, funding). The editorial office may request supporting documentation before granting approval.
Can I submit to multiple journals simultaneously?
No. JBBS requires exclusive submission. If you have related manuscripts under review elsewhere, disclose them in your cover letter for transparency.
Do special issue submissions go through the same review process?
Yes. All manuscripts undergo single-blind peer review to uphold uniform quality. Guest editors collaborate with JBBS editors, but final decisions rest with the Editor-in-Chief.
Can industry collaborators participate?
Absolutely. Industry-sponsored research is welcome when conflicts of interest, funding, and data access are fully disclosed, and studies meet JBBS ethics standards.
Do I need to submit a preprint?
Preprints are optional. If you have posted one, include the DOI in your submission. JBBS celebrates open science and encourages community feedback prior to peer review.
Submit Your Manuscript or Proposal Today
Join a global community of researchers shaping the future of biotechnology and biomedical science. Whether you are submitting a breakthrough study or orchestrating a special issue, the JBBS editorial team is ready to support you end-to-end.
Last updated: September 2025. The Call for Papers schedule and waiver availability are reviewed quarterly to reflect community priorities and emerging scientific needs.
